CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - NYSE:CRL - US1598641074 - Common Stock
171.9 USD
+4.87 (+2.92%)
CRL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. CRL has only an average score on both its financial health and profitability. CRL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRL was profitable.
CRL had a positive operating cash flow in the past year.
CRL had positive earnings in each of the past 5 years.
CRL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CRL has a Return On Assets of -0.92%. This is comparable to the rest of the industry: CRL outperforms 57.14% of its industry peers.
CRL's Return On Equity of -2.06% is in line compared to the rest of the industry. CRL outperforms 55.36% of its industry peers.
CRL has a better Return On Invested Capital (5.72%) than 73.21% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CRL is significantly below the industry average of 14.93%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROIC | 5.72% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
CRL's Profit Margin has declined in the last couple of years.
CRL has a better Operating Margin (11.64%) than 71.43% of its industry peers.
CRL's Operating Margin has been stable in the last couple of years.
CRL's Gross Margin of 35.03% is on the low side compared to the rest of the industry. CRL is outperformed by 62.50% of its industry peers.
In the last couple of years the Gross Margin of CRL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CRL is destroying value.
Compared to 1 year ago, CRL has less shares outstanding
Compared to 5 years ago, CRL has more shares outstanding
CRL has a better debt/assets ratio than last year.
2.2 Solvency
CRL has an Altman-Z score of 2.32. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.32, CRL is in line with its industry, outperforming 58.93% of the companies in the same industry.
CRL has a debt to FCF ratio of 4.04. This is a neutral value as CRL would need 4.04 years to pay back of all of its debts.
CRL has a better Debt to FCF ratio (4.04) than 71.43% of its industry peers.
A Debt/Equity ratio of 0.70 indicates that CRL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.70, CRL is not doing good in the industry: 73.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Altman-Z | 2.32 |
ROIC/WACC0.57
WACC10.02%
2.3 Liquidity
A Current Ratio of 1.36 indicates that CRL should not have too much problems paying its short term obligations.
CRL's Current ratio of 1.36 is on the low side compared to the rest of the industry. CRL is outperformed by 78.57% of its industry peers.
CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL has a Quick ratio of 1.10. This is in the lower half of the industry: CRL underperforms 78.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.49% over the past year.
CRL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.93% yearly.
CRL shows a decrease in Revenue. In the last year, the revenue decreased by -1.21%.
The Revenue has been growing by 9.09% on average over the past years. This is quite good.
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
3.2 Future
Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 5.95% on average per year.
Based on estimates for the next years, CRL will show a small growth in Revenue. The Revenue will grow by 2.43% on average per year.
EPS Next Y-0.27%
EPS Next 2Y2.3%
EPS Next 3Y4.52%
EPS Next 5Y5.95%
Revenue Next Year-1.08%
Revenue Next 2Y0.5%
Revenue Next 3Y2.15%
Revenue Next 5Y2.43%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.05 indicates a correct valuation of CRL.
Compared to the rest of the industry, the Price/Earnings ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 94.64% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.02. CRL is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 15.92, which indicates a correct valuation of CRL.
Based on the Price/Forward Earnings ratio, CRL is valued cheaper than 89.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.57. CRL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.05 | ||
| Fwd PE | 15.92 |
4.2 Price Multiples
98.21% of the companies in the same industry are more expensive than CRL, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CRL is valued cheaply inside the industry as 92.86% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.62 | ||
| EV/EBITDA | 11.53 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.8
EPS Next 2Y2.3%
EPS Next 3Y4.52%
5. Dividend
5.1 Amount
CRL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:CRL (10/13/2025, 11:36:36 AM)
171.9
+4.87 (+2.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.46%
Inst Owner Change-1.02%
Ins Owners0.88%
Ins Owner Change6.07%
Market Cap8.46B
Analysts71.3
Price Target182.76 (6.32%)
Short Float %5.27%
Short Ratio2.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.56%
Min EPS beat(2)11.44%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)11.21%
Min EPS beat(4)4.03%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)10.55%
EPS beat(12)12
Avg EPS beat(12)8.62%
EPS beat(16)16
Avg EPS beat(16)6.82%
Revenue beat(2)2
Avg Revenue beat(2)3.59%
Min Revenue beat(2)3.45%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.63%
Min Revenue beat(4)0.91%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)10
Avg Revenue beat(12)1.88%
Revenue beat(16)11
Avg Revenue beat(16)1.12%
PT rev (1m)3.47%
PT rev (3m)16.43%
EPS NQ rev (1m)-0.04%
EPS NQ rev (3m)-1.22%
EPS NY rev (1m)0.74%
EPS NY rev (3m)6.15%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)2.82%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)2.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.05 | ||
| Fwd PE | 15.92 | ||
| P/S | 2.1 | ||
| P/FCF | 14.62 | ||
| P/OCF | 10.74 | ||
| P/B | 2.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.53 |
EPS(TTM)10.71
EY6.23%
EPS(NY)10.8
Fwd EY6.28%
FCF(TTM)11.76
FCFY6.84%
OCF(TTM)16
OCFY9.31%
SpS81.87
BVpS68.14
TBVpS-3.77
PEG (NY)N/A
PEG (5Y)1.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROCE | 7.24% | ||
| ROIC | 5.72% | ||
| ROICexc | 5.88% | ||
| ROICexgc | 13.43% | ||
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% | ||
| FCFM | 14.36% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexcg growth 3Y-14.69%
ROICexcg growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 48.58% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 4.15 | ||
| Cash Conversion | 87.57% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.32 |
F-Score4
WACC10.02%
ROIC/WACC0.57
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
EPS Next Y-0.27%
EPS Next 2Y2.3%
EPS Next 3Y4.52%
EPS Next 5Y5.95%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
Revenue Next Year-1.08%
Revenue Next 2Y0.5%
Revenue Next 3Y2.15%
Revenue Next 5Y2.43%
EBIT growth 1Y-25.61%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year34.27%
EBIT Next 3Y14.36%
EBIT Next 5Y10.95%
FCF growth 1Y99.92%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y25.98%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%